SMTI$21.11
Chart
Performance
Key Stats
AI SMTI Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldSanara MedTech Inc. shows mixed signals. Fundamentally, it's experiencing revenue growth but remains unprofitable with negative earnings per share. Technically, indicators suggest a bearish trend with multiple moving averages indicating sell signals. Thematic exposure is neutral. Further analysis is recommended to determine its long-term viability and potential for turnaround.
Thematic
Sanara MedTech operates in the medical technology sector, focusing on surgical, wound, and skincare products. While the healthcare and medtech sectors generally offer stable demand, specific thematic tailwinds such as AI in healthcare or advanced wound care innovations are not strongly indicated by the provided data. The company's product pipeline is mentioned, but specific thematic alignments are not detailed.
Fundamental
Sanara MedTech is growing its revenue, but profitability remains a significant concern with consistent net losses and negative EPS. The company's balance sheet shows increasing debt and decreasing cash reserves over the past few years, although recent quarters show some improvement in cash flow. Valuation metrics like P/S are high relative to revenue, and P/E is not applicable due to losses.
Technical
Technical indicators across various timeframes (1m, 5m, 15m, 30m, 1h, 2h, 4h, 1d) overwhelmingly suggest 'Sell' actions, primarily driven by Exponential and Simple Moving Averages. Oscillators like RSI and Stochastic RSI are mixed, leaning towards 'Buy' or 'Neutral' in shorter timeframes, but the overall moving average trend indicates strong bearish momentum.
| Factor | Score |
|---|---|
| Healthcare Sector Demand | 70 |
| Advanced Wound Care Innovation | 65 |
| Antimicrobial Product Development | 60 |
| Market Penetration | 40 |
| Regulatory Landscape | 50 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 75 |
| Balance Sheet Health | 50 |
| Cash Flow | 60 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 45 |
| Volume Confirmation | 55 |
| Support & Resistance | 55 |
| Oscillator Signals | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Post-Market Strength
The stock closed at $25.53, down 0.47% on the day. However, it showed strength in post-market trading, rising 0.67% to $25.7, suggesting positive investor sentiment following the regular trading session.
Low Price-to-Sales Ratio
The Price-to-Sales (P/S) ratio is 3.2 TTM, which is relatively low compared to historical periods (e.g., 10.9 in 2021), indicating potential undervaluation based on revenue generation.
Bearish Points (8)
Consistent Net Losses
The company has reported net losses for all periods presented (2021-2024), with a significant loss of -$9.66 million in 2024. The TTM net income is also negative at -$7.92 million.
Negative Net Margins
Net margins are consistently negative and have widened from -32.8% in 2021 to -11.2% in 2024, indicating deteriorating profitability relative to revenue.
Calendar
May 2019
10
Next Dividend Date
August 2025
13
Next Earnings Date
H: $
A: $
L: $
H: 25.40M
A: 25.15M
L: 24.90M
Profile
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Seasonals
Price Target
49.00 USD
The 39 analysts offering 1 year price forecasts for SMTI have a max estimate of 53.00 and a min estimate of 45.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in advanced wound care, regenerative medicine, and surgical biologics, focusing on similar chronic and acute wound solutions as SMTI.
Weight: 90
Global medical technology company with a significant and established advanced wound management division, offering a broad portfolio of wound care products that directly compete with SMTI.
Weight: 88
Specializes in medical products and technologies, with a strong focus on advanced wound care solutions, ostomy care, and continence care, making it a key competitor in the wound healing space.
Weight: 85
Provides surgical instruments, tissue technologies, and regenerative solutions for wound and soft tissue reconstruction, often in complex surgical scenarios similar to SMTI's focus.